Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021
Diagnosis and Management of the Antiphospholipid Syndrome
NEJM 378:2010-2021, Garcia, D. & Erkan, D., 2018
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Management of Anticoagulants in Patients Undergoing Endoscopic Procedure
www.UptoDate.com, Dec, Kamath, P.S., 2018
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
Stroke 46:1120-1122, Tung, J.M.,et al, 2015
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Spinal Haemorrhage During Anticoagulant Regimen for Thromboprophylaxis: A Unique Form of Central Nervous System Haemorrhage
JNNP 83:746-752, Furlan, J.C.,et al, 2012
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
NEJM 367:625-635, Olesen, J.B.,et al, 2012
Hemostatic Therapy Should be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2535-2536,2539, Diringer, M. & Zazulia, A.R., 2012
Hemostatic Therapy Should not be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2537-2538,2539, Stapf, C., 2012
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage
Stroke 41:2860-2866, Majeed,A.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Managing the Anticoagulated Patient with Atrial Fibrillation at High Risk of Stroke Who Needs Coronary Intervention
BMJ 337:1110-1111, Lip,G.Y.H., 2008